| |
 |
|
|
|
|
|
Poster: 280
Visits: 106
Title: Interim Analysis of a Phase 1b Study Evaluating the Safety of GS-9820, a Second-Generation PI3Kd-Inhibitor, in Relapsed/Refractory Lymphoid Malignancies
Authors: Arnon Kater ,
Centre: Academic Medical Center Amsterdam, Lymphoma and Myeloma Center
|
|
You must be registered to reply or comment.
|
|
INTERIM ANALYSIS OF A PHASE 1B STUDY EVALUATING THE SAFETY OF GS-9820, A SECOND-GENERATION PI3KD-INHIBITOR, IN RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES
|
|
| You must be registered to reply or comment. |
|
|
|
|
|
|
| Most viewed poster for this congress |
|
|
Poster: 9
Visits: 649
Title: Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update from a Phase II Clinical Trial
Authors: Michael Wang ,
Centre: The University of Texas MD Anderson Cancer Center
|
|
|
|
|
|
|
| Poster most viewed in this topic |
|
|
Poster: 154
Visits: 188
Title: NR4A3 suppresses lymphomagenesis by induction of apoptosis and serves as a drug target for lymphoma therapy
Authors: Alexander Deutsch ,
Centre: Clinical Devision of Hematology
|
|
|
|
